Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells

Human Immunology

Volumn 59, Issue 8, 1998, Pages 463-471

  Siklodi, Botond ^a,c   Vogt, Anne B ^b   Kropshofer, Harald ^b   Falcioni, Fiorenza ^a   Molina, Margarita ^a   Bolin, David R ^a   Campbell, Robert ^a   Hämmerling, Günter J ^b   Nagy, Zoltan A ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Biogal Inc   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR1 ANTIGEN; PEPTIDE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CELL LINE; HALF LIFE TIME; HLA TYPING; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN BINDING;

ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; BINDING SITES; CELL LINE, TRANSFORMED; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HLA-DR1 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 0031904199     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(98)00038-X     Document Type: Article

References (33)

1. Rudensky AY, Preston-Hurlburt P, Hong S-C, Barlow A, Janeway Jr CA: Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622, 1991.
2. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DAA, Strominger JL: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764, 1992.
3. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC: Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215, 1994.
4. Ghosh, P, Amaya M, Mellins E, Wiley DC: The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378:457, 1995.
5. Germain RN, Hendrix LR: MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 353:134, 1991.
6. Buus S, Sette A, Colon SM, Jenis DM, Grey HM: Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell 47:1071, 1986.
7. d. Proc Natl Acad Sci USA 88:4661, 1991.
8. Lanzavecchia A, Reid PA, Watts C: Irreversible association of peptides with class II MHC molecules in living cells. Nature 357:249, 1992.
9. Bot A, Bot S, Antohi S, Karjalainen K, Bona C: Kinetics of generation and persistance on membrane class II molecules of a viral peptide expressed on foreign and self proteins. J Immunol. 157:3436, 1996.
10. Adorini L, Appella E, Dori G, Cardinaux F, Nagy ZA: Competition for antigen presentation in living cells involves exchange of peptides bound by class II MHC molecules. Nature 342:800, 1989.
11. Harding CV, Roof RW, Unanue ER: Turnover of Ia-peptide complexes is facilitated in viable antigen-presenting cells: biosynthetic turnover vs. peptide exchange. Proc Natl Acad Sci USA 86:4230, 1989.
12. Marsh EW, Dalke DP, Pierce SK: Biochemical evidence for the rapid assembly and disassembly of processed antigen-major histocompatibility complex class II complexes in acidic vesicles of B cells. J Exp Med. 175:425, 1992.
13. Nelson CA, Petzold SJ, Unanue ER: Peptides determine the lifespan of MHC class II molecules in the antigen presenting cell. Nature 371:250, 1994.
14. Lee JM, Watts TH: On the dissociation and reassociation of MHC class II-foreign peptide complexes. Evidence that brief transit through an acidic compartment is not sufficient for binding site regeneration. J Immunol. 144:1829, 1989.
15. Müller KP, Schumacher J, Kyewski BA: Half-life of antigen/major histocompatibility complex class II complexes in vivo: intra- and interorgan variations. Eur J Immunol. 23:3203, 1993.
16. Sloan VS, Cameron P, Porter G, Gammon G, Amaya M, Mellins E, Zaller DM: Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375:802, 1995.
17. Vogt AB, Kropshofer H, Moldenhauer G, Hämmerling GJ: Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci USA 93:9724, 1996.
18. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ: Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 15:6144, 1996.
19. Weber DA, Evavold BD, Jensen PE: Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274:618, 1996.
20. Hammer J, Takacs B, Sinigaglia F: Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 176:1007, 1992.
21. Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs B, Sinigaglia F: Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197, 1993.
22. Hammer J, Belunis C, Bolin D, Papadopoulos J, Walsky R, Higelin J, Danho W, Sinigaglia F, Nagy ZA: High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc Natl Acad Sci USA 91:4456, 1994.
23. Falcioni F, Shah H, Vidović D, Morimoto C, Belunis C, Bolin D, Nagy ZA: Influence of CD26 and integrins on the antigen sensitivity of human memory T cells. Human Immunol. 50:79, 1996.
24. Vidović D, Falcioni F, Siklodi B, Belunis CJ, Bolin DR, Ito K, Nagy ZA: Down-regulation of class II major histocompatibility complex molecules on antigen presenting cells by antibody fragments. Eur J Immunol. 25:3349, 1995.
25. Barany G, Merrifield RB: The peptides. New York, Academic Press, 2:1, 1980.
26. Ito K, Bian HJ, Molina M, Han J, Magram J, Saar E, Belunis C, Bolin DR, Arceo R, Campbell R, Falcioni F, Vidović D, Hammer J, Nagy ZA: HLA-DR4-IE chimeric transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 183:2635, 1996.
27. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB: HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6:293, 1997.
28. Hammer J, Bono B, Gallazzi F, Belunis C, Nagy ZA, Sinigaglia F: Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 180:2353, 1994.
29. van Ham SM, Grüneberg U, Malcherek G, Bröker I, Melms A, Trowsdale J: Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their binding motifs. J Exp Med 184:2019, 1996.
30. Katz JF, Stebbins C, Appella E, Sant AJ: Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med 184:1747, 1996.
31. Harding CV, Unanue ER: Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 346:574, 1990.
32. Demotz S, Grey HM, Sette A: The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 249:1028, 1990.
33. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue ER: Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 6:727, 1997.